Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to cisplatin

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 6, 2015, Pages 9931-9936

  Yang, Zhihong ^a   Zhao, Juan ^b  

^a YANTAISHAN HOSPITAL   (China)

^b Xiangyang Central Hospital   (China)

Author keywords

Cisplatin resistance; Gene polymorphism; Hepatocellular carcinoma; Sensitivity to cisplatin; Susceptibility

Indexed keywords

CISPLATIN;

ADULT; APE1 GENE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG SENSITIVITY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING; ULTRAVIOLET SPECTROPHOTOMETRY; XRCC1 GENE;

EID: 84938323448     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. [1] Cui X, Li Z, Gao PJ, Gao J, Zhu JY. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int 2015; 14: 157-63.
2. [2] Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F, Xia Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012; 423: 826-31.
3. [3] Yang WL, Wei L, Huang WQ, Li R, Shen WY, Liu JY, Xu JM, Li B, Qin Y. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth. Oncol Rep 2014; 31: 2328-34.
4. [4] Leveille-Webster CR, Arias IA. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin Cancer Res 1996; 2: 695-706.
5. [5] Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 2009; 273: 201-9.
6. [6] Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A, Xu S, Røe OD, Wang M, Zhang R, Yang L, Zhou J. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells. Cell Death Dis 2014; 5: e1551.
7. [7] Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009; 66: 298-304.
8. [8] Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, Sun X, Zhang L, Lv J, Yang F. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. Hum Vaccin Immunother 2014; 10: 2983-91.
9. [9] Brotodihardjo AE, Tait N, Weltman MD, Liddle C, Little JM, Farrell GC. Hepatocellular carcinoma in western Sydney. Aetiology, changes in incidence and opportunities for better outcomes. Med J Aust 1994; 161: 433-5.
10. [10] Alswat KA, Sanai FM, Altuwaijri M, Albenmousa A, Almadi M, Al-Hamoudi WK, Abdo AA. Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population. Hepat Mon 2013; 13: e7612.
11. [11] Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer 2012; 107: 1672-7.
12. [12] Li J, Ju Y. Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis. Iran J Med Sci 2015; 40: 2-12.
13. [13] Xu J, Ma J, Zong HT, Wang SY, Zhou JW. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis. Genet Mol Res 2014; 13: 1438-46.
14. [14] Karahalil B, Bohr VA, Wilson DM III. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol 2012; 31: 981-1005.
15. [15] Shen E, Liu C, Wei L, Hu J, Weng J, Yin Q, Wang Y. The APE1 Asp148Glu polymorphism and colorectal cancer susceptibility: a meta-analysis. Tumour Biol 2014; 35: 2529-35.
16. [16] Gu AQ, Wang WM, Chen WY, Shi CL, Lu JH, Han JQ. XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects. Int J Clin Exp Med 2015; 8: 145-54.
17. [17] Yun YX, Dai LP, Wang P, Wang KJ, Zhang JY, Xie W. Association of polymorphisms in X-ray repair cross complementing 1 gene and risk of esophageal squamous cell carcinoma in a Chinese population. Biomed Res Int 2015; 2015: 509215.
18. [18] Patrono C, Sterpone S, Testa A, Cozzi R. Polymorphisms in base excision repair genes: Breast cancer risk and individual radiosensitivity. World J Clin Oncol 2014; 5: 874-82.
19. [19] Sakano S, Ogawa S, Yamamoto Y, Nishijima J, Miyachika Y, Matsumoto H, Hara T, Matsuyama H. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol 2013; 1: 403-410.
20. [20] Zhao DY, Cheng L, Yu J, Shen H. XRCC1 genetic polymorphism Arg339Gln, Arg194Trp, Arg2-80His and gastric cancer risk: an evidence based decision. Cancer Biomark 2014; 14: 449-56.
21. [21] Gao CM, Ding JH, Li SP, Liu YT, Cao HX, Wu JZ, Tang JH, Tajima K. Polymorphisms in XRCC1 gene, alcohol drinking, and risk of colorectal cancer: a case-control study in Jiangsu Province of China. Asian Pac J Cancer Prev 2014; 14: 6613-8.